Bayer divestment completed

Bayer HealthCare (BHC) has announced that the anti-infectives research division of the company has been switched to AiCuris GmbH.

BHC will retain a small investment interest in the newly founded company and AiCuris GmbH will be housed in BHC’s Pharma-und Chemiepark in Wuppertal, Germany.

“The divestment that has now been concluded according to plan has allowed us to retain valuable jobs and thus strength the Wuppertal research site,” said Dr Gunnar Riemann, head of BHC’s Pharmaceuticals Division.

“I am certain that the highly qualified staff will enjoy a productive environment in the new company.”

Patent rights, licences, development products and research projects will all be taken over by AiCuris GmbH and BHC will offer its “high-performance technology platform and product development know-how” to the new company for the term of a limited-period service agreement between the two.

The new company, which will have up to 30 staff, will investigate active treatments for and solutions to diseases caused by bacterial and viral infections.

© Adfero Ltd